{"id":2646,"date":"2017-01-23T09:10:43","date_gmt":"2017-01-23T08:10:43","guid":{"rendered":"http:\/\/semmelweis.hu\/patologia1\/?page_id=2646"},"modified":"2025-12-09T11:38:53","modified_gmt":"2025-12-09T10:38:53","slug":"tumour-biology-tumour-metabolism-research-group","status":"publish","type":"page","link":"https:\/\/semmelweis.hu\/patologia1\/en\/research\/tumour-biology-tumour-metabolism-research-group\/","title":{"rendered":"Tumour Biology – Tumour Metabolism Research Group"},"content":{"rendered":"

Tumour biology \u2013 Tumour metabolism research group<\/strong><\/p>\n

\"\"<\/a>Failures in signalling pathways<\/strong> could contribute to the alterations occurring in cellular metabolism of tumour cells. As a key element of signalling network, mTOR <\/strong>(mammalian target of rapamycin) regulates several cellular functions depending on the available nutrients, energy and other factors\/the oscillating energy status, nutrient and other factor availability. Appropriate regulation of mTOR can influence cellular metabolic activity<\/strong> including glucose and glutamine uptake, glutaminolysis, lipid metabolism or oxidative phosphorylation. Deregulated mTOR signalling are well-known in changes leading to carcinogenesis. Our results also highlight that there is a significant correlation among high mTOR activity \u2013 especially in case it is mTORC2 complex related \u2013, worse prognosis and therapy resistance. We study the role and importance of mTORC1 and C2 complexes<\/strong> in relation of therapy resistance, metabolic adaptation and metabolic plasticity<\/strong> of tumours. In parallel, we investigate the tissue and metabolic heterogeneity, immune-microenvironment<\/strong> and additionally its potential diagnostic and therapeutic impact in a wide-range of tumours. Beside the characterisation of human tumour tissues, we involve in vitro and in vivo model systems in our experimental designs. We established the 3D bioprinting technique in tumour modelling<\/strong>, 3D bioprinted tissue-like structures. In relation to these, our aims are both optimising and characterising the experimental approach of metabolic adaptation and developing the pre-selection method of a better anti-tumoural agent. As a matter of course, molecular biology and analytical chemistry methods and even metabolic profiling (both metabolite and protein studies) gain important roles in these studies.
\n

\n

Related own publications <\/h2>\n
\n<\/p>\n